|
|
11388 Sorrento Valley Road
San Diego, CA 92121 USA
phone:(858) 794-8889
fax:858.704.8311
|
|
| Symbol |
HALO |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.halozyme.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Recombinant human enzymes for tor infertility, opthalmology, and oncology communities. |
|
| Management |
| Jonathan E. Lim, M.D., President, Chief Executive Officer and member of the Board of Directors; Gregory I. Frost, Ph.D., Vice President, Chief Scientific Officer and member of the Board of Directors; Kurt Gustafson, Vice President, Chief Financial Officer; Jonathan Leff, M.D., Vice President, Chief Medical Officer; Robert J. Little, Vice President, Chief Commercial Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| hyaluronidase, hyaluronan, biopharmaceutical, oncology, dermatology |
|
|
|
| Description |
|
Halozyme Therapeutics, Inc. is a therapeutically driven biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the infertility, ophthalmology, and oncology communities. |
|
| Products / Services |
The company's broad product portfolio is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's lead products offer a safe and pure alternative to existing slaughterhouse-derived extracts that carry risks of animal pathogen contamination and immunogenicity.
|
|
| Technology / Differentiation |
| Our technology is based on recombinant human PH20 (rHuPH20), a human synthetic version of hyaluronidase that degrades hyaluronic acid, a space-filling, gel-like substance that is a major component of tissues throughout the body, such as skin and cartilage. The PH20 enzyme is a naturally occurring enzyme that digests hyaluronic acid to temporarily break down the gel, thereby facilitating the penetration and diffusion of other drugs and fluids that are injected under the skin or in the muscle. |
|
|
| Status |
| The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to significantly impact the quality of medicine while creating long-term shareholder value. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
